XTRENBO 120 mg/1.7mL
Denosumab-qbde · INJECTION · Hikma Pharmaceuticals USA Inc.
Xtrenbo (denosumab-qbde) is a prescription injection used to treat bone loss and reduce the risk of fractures in patients with certain conditions affecting bone strength. It works by blocking a protein that causes bone breakdown, helping to preserve bone density.
Key Facts
- Brand Name
- XTRENBO
- Generic Name
- Denosumab-qbde
- NDC Code (Product)
0143-9166- Manufacturer
- Hikma Pharmaceuticals USA Inc.
- Strength
- 120 mg/1.7mL
- Dosage Form
- INJECTION
- Route
- SUBCUTANEOUS
- Marketing Status
- Application #
- BLA761439
- Drug Class
- RANK Ligand Inhibitor [EPC]
- Marketing Start
- 01/08/2026
Recall History
No Recall HistoryFrequently Asked Questions
What is XTRENBO used for?
Xtrenbo (denosumab-qbde) is a prescription injection used to treat bone loss and reduce the risk of fractures in patients with certain conditions affecting bone strength. It works by blocking a protein that causes bone breakdown, helping to preserve bone density.
Is XTRENBO a controlled substance?
XTRENBO is not classified as a controlled substance by the DEA.
What is the generic name for XTRENBO?
The generic name for XTRENBO is Denosumab-qbde. There are 1 other brand versions of Denosumab-qbde.
What is the NDC code for XTRENBO 120 mg/1.7mL?
The NDC (National Drug Code) for XTRENBO 120 mg/1.7mL is 0143-9166, listed by Hikma Pharmaceuticals USA Inc..